Ralph Riley

Company: Johnson & Johnson

Job title: Director - Precision Medicine Access & Policy Strategy

Bio:

Ralph Riley, MBA is Global Director Precision Medicine Access and Policy Strategy at Johnson & Johnson. In his more than twenty-years at J&J he has worked across multiple disease areas to develop and commercialize testing to enable patient identification strategies and worked to shape policy to enable improved access policy for testing.

Ralph has co-authored research articulating the value of diagnostics and precision medicine, the utility of next generation sequencing in lung cancer and lead research in epidemiology and modeling the use of biomarkers for chronic disease. He has spoken at many personalized medicine and access focused conferences regarding opportunities for evidence generation and access strategy related to testing and currently serves as a board member for From Testing to Targeted Treatment (FT3)- a multi-stakeholder organization seeking to improve access to testing for targeted therapies globally.

Seminars:

Commercial Considerations for Digital Pathology Assets Supporting Therapeutics 9:30 am

While the promise of digital pathology is clear, clinical adoption at scale is still out of reach. This workshop will explore the commercial realities of deploying digital pathology tools beyond clinical trials, examining where value is created, who benefits, and how success is measured. Advancing this field starts with asking the right questions… Join this…Read more

day: Pre-Conference Workshop Day